Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Tenet Healthcare Corporation (THC) has a Wall Street consensus price target of $257.45, based on estimates from 32 covering analysts. With the stock currently trading at $239.39, this represents a potential upside of +7.5%. The company has a market capitalization of $21.04B.
Analyst price targets range from a low of $224.00 to a high of $288.00, representing a 25% spread in expectations. The median target of $260.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, THC trades at a trailing P/E of 15.5x and forward P/E of 14.1x. The forward PEG ratio of 0.43 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +5.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $311.13, with bear and bull scenarios of $75.14 and $434.61 respectively. Model confidence stands at 62/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how THC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for THC is $257.45, close to the current price of $239.39 (7.5% implied move). Based on 32 analyst estimates, the stock appears fairly valued near current levels.
THC has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $257.45 implies 7.5% upside from current levels.
With a forward P/E of 14.1242x, THC trades at a relatively low valuation. The consensus target of $257.45 implies 7.5% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $288 for THC, while the most conservative target is $224. The consensus of $257.45 represents the median expectation. Our quantitative valuation model projects a bull case target of $435 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
THC is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 7 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month THC stock forecast based on 32 Wall Street analysts shows a consensus price target of $257.45, with estimates ranging from $224 (bear case) to $288 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $311, with bear/bull scenarios of $75/$435.
Our quantitative valuation model calculates THC's fair value at $311 (base case), with a bear case of $75 and bull case of $435. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 62/100.
THC trades at a forward P/E ratio of 14.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 15.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
THC appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $257.45 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
THC analyst price targets range from $224 to $288, a 25% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $257.45 consensus represents the middle ground. Our model's $75-$435 range provides an independent fundamental perspective.